Expectedness in Pharmacovigilance Explained: Definition, Sources, and Practical Examples

📌 Table of Contents

1. Introduction to Expectedness in Pharmacovigilance
2. What Does Expected Mean in Pharmacovigilance?
3. Sources of Expectedness in Pharmacovigilance
4. Step-by-Step Expectedness Assessment Process
5. Expectedness Assessment Examples
6. Common Challenges and Best Practices
7. Conclusion: Why Expectedness Matters

Introduction to Expectedness in Pharmacovigilance

While learning pharmacovigilance, one of the most important concepts I came across is expectedness. At first, it may sound like a simple term, but in real pharmacovigilance practice, expectedness plays a critical role in how adverse events are classified, reported, and communicated to regulatory authorities.

In simple terms, expectedness helps determine whether an adverse event is already known for a drug based on available safety information, or whether it represents a new and unanticipated finding. This assessment has a direct impact on reporting timelines, regulatory compliance, and ongoing patient safety monitoring.

As a fresher learning pharmacovigilance, understanding expectedness helped me bridge the gap between theoretical concepts and real-world case processing activities.

“Expectedness determines whether an adverse event is known and previously documented for a drug or not, and this influences how the event should be reported.”

What Does “Expected” Mean in Pharmacovigilance?

In pharmacovigilance, every reported adverse event is evaluated not only for seriousness and causality, but also for expectedness.

An expected adverse event refers to an event that has already been documented in the approved safety reference information for a drug.

An unexpected adverse event is one that is not mentioned in the safety reference, or one that differs in its nature, severity, or frequency from what is already known about the product.

From a regulatory perspective, expectedness is not based on personal opinion or assumption. It is always assessed by systematically comparing the reported event with official safety reference documents. This structured approach helps maintain consistency in safety reporting and minimizes subjective interpretation.

Sources of Expectedness in Pharmacovigilance (Safety Reference Documents)

In pharmacovigilance, expectedness is assessed by comparing the reported adverse event with authorized safety reference documents. These documents describe the known safety profile of a drug and act as the official basis for determining whether an event is expected or unexpected.

The reference document used for expectedness assessment depends on whether the case originates from a clinical trial or a post-marketing setting.

Investigator’s Brochure (IB) and Its Role in Expectedness Assessment

The Investigator’s Brochure is a comprehensive document that summarizes all available clinical and non-clinical safety data of an investigational product.

• Primarily used for clinical trial cases
• Contains known adverse events, risks, and safety findings
• Expectedness in trials is assessed against the latest approved version of the IB

SmPC, Package Insert, and Post-Marketing Expectedness

The Summary of Product Characteristics (SmPC) or package insert is an approved regulatory document that describes the safety, efficacy, and usage of a marketed product.

• Used mainly for post-marketing cases
• Lists known adverse reactions and their characteristics
• Serves as a key reference for expectedness assessment after product approval

Company Core Data Sheet (CCDS) and Core Safety Information (CSI)

The Company Core Data Sheet (CCDS) or Core Safety Information (CSI) is a company-defined global safety reference.

• Used for global consistency in safety reporting
• Aligns expectedness assessment across different countries
• Often acts as the reference safety information (RSI) for regulatory reporting

How Is Expectedness Assessed in Pharmacovigilance?

Expectedness assessment follows a structured and objective process:

• The reported adverse event is first coded correctly using MedDRA
• The coded event is compared with the adverse reactions listed in the applicable safety reference document

Outcome of comparison:

• If the event is listed → Expected
• If the event is not listed → Unexpected

This comparison must always be based on documented evidence, not assumptions.

Which Reference Document Is Authoritative?

• Clinical trial cases: Investigator’s Brochure (latest approved version)
• Post-marketing cases: SmPC / Package Insert / CCDS / CSI (current version)

Using the most recent version of the safety reference document is essential to ensure regulatory compliance.

Expected vs Unexpected — Official Regulatory Definitions

Regulatory authorities provide clear guidance on how expectedness should be interpreted.

According to ICH, an adverse event is considered unexpected if it is not consistent with the applicable product information in terms of its nature, severity, or frequency.

The FDA emphasizes expectedness assessment mainly to determine expedited reporting requirements, particularly in the context of clinical trials.

The European Medicines Agency highlights the importance of using the SmPC and core safety information as the primary reference for expectedness assessment in post-marketing safety reporting.

If an adverse event is listed in the Investigator’s Brochure or the approved product label under adverse reactions, it is generally considered expected.

Step-by-Step Process for Expectedness Assessment

As a learner, breaking the concept of expectedness into clear steps made it much easier for me to understand and apply it practically. In real pharmacovigilance work, expectedness assessment follows a structured and well-defined workflow.

Step-by-step workflow

1. Retrieve the most current safety reference document
   Ensure that the latest approved version of the Investigator’s Brochure, SmPC, or other applicable reference is used.

2. Identify and code the adverse event using MedDRA
   Correct coding using MedDRA is essential before assessing expectedness.

3. Compare the coded term with listed adverse reactions
   The coded event is checked against the adverse reactions mentioned in the reference document.

4. Classify the event
   Based on the comparison, the event is classified as either Expected or Unexpected.

5. Document the assessment clearly
   The expectedness assessment should be documented accurately in the case narrative or safety database.

Following a structured workflow helps ensure consistency, regulatory compliance, and audit readiness.

Expectedness Assessment Examples (Dummy Case Scenarios)

Example 1

A vaccinated patient reports fever after administration.
Fever is listed in the product label.
➡ Expected adverse event

Example 2

A drug is known to cause skin rash, and rash is listed in the SmPC.
➡ Expected adverse event

Example 3

A patient develops a new neurological symptom that is not mentioned anywhere in the safety label.
➡ Unexpected adverse event

Example 4

A pregnancy outcome is reported, but no pregnancy-related information exists in the safety reference document.
➡ Unexpected adverse event

These examples highlight that expectedness assessment is based strictly on documented safety information, not assumptions or clinical opinions.

Common Challenges in Expectedness Assessment

While learning expectedness, I noticed several challenges that beginners should be aware of:

• Ambiguous or unclear wording in safety labels
• Availability of multiple versions of reference documents
• Incorrect selection of MedDRA terms
• Use of an outdated Investigator’s Brochure

Being aware of these challenges helps reduce classification errors and compliance risks.

Tools and Best Practices for Expectedness Assessment

Some practical tips that helped me during learning include:

• Always complete MedDRA coding before assessing expectedness
• Use only the latest approved version of the IB or SmPC
• Search reference documents using keywords and relevant section headings
• Maintain proper version control for all safety reference documents

Good documentation and review practices make expectedness assessment more accurate and reliable.

Conclusion: Why Expectedness Matters in Pharmacovigilance

Expectedness is a foundational concept in pharmacovigilance that directly impacts regulatory compliance, reporting timelines, and patient safety.

Key takeaways

• Expectedness determines whether an adverse event is known or new
• Always refer to current and approved safety reference documents
• Accurate MedDRA coding is essential for correct assessment
• Proper classification supports timely and compliant reporting

As a fresher learning pharmacovigilance, understanding expectedness has helped me appreciate how structured, evidence-based, and regulated PV decision-making is.

📌 If you have questions or would like more learning-focused posts, feel free to share your thoughts in the comments. 

You might also find these posts helpful:

🔗 Seriousness vs Severity in Pharmacovigilance: A Simple Guide with Examples

🔗 Learning ICSR Processing in Pharmacovigilance: Practical Case Scenarios for Beginners

🔗 Signal Detection in Pharmacovigilance: Concepts, Methods, and Examples

🔗 Pharmacovigilance Narrative Writing Practice: ICSR Examples for Beginners

🔗 Medically Significant Events in Pharmacovigilance (PV)

🔗 Country-Specific Pharmacovigilance Regulatory Guidelines: A Global Overview